-
-
-
-
-
-
-
Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
-
-
-
-
-
-
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Raised to $45 at Stifel: Lead Programs Have 2026 Catalysts
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $17 at RBC Capital
-
-
-
-
-
-
-
Leerink on Regenxbio Inc. (RGNX): 'the path to accelerated approval is likely clear, valuation is undemanding, and balance sheet robust'
-
416,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

